EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Perioperative Management of Ruxolitinib in Primary Myelofibrosis During Coronary Artery Bypass Graft Surgery

Michael Kay iD, Martin Yates, Emma O'Donovan, Lauren Tully

Interdisciplinary CardioVascular and Thoracic Surgery · 03.08.2026 · 41 (8)

DOI: 10.1093/icvts/ivag211 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Interdisciplinary CardioVascular and Thoracic Surgery, online erschienen am 30.07.2026. Verfasst von Michael Kay und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom. Hauptthemen laut MEDLINE: Pyrazoles, Primary Myelofibrosis, Coronary Artery Bypass, Perioperative Care. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently treated with the Janus kinase (JAK) inhibitor ruxolitinib. Perioperative management of ruxolitinib presents a clinical dilemma. Continued therapy may increase the risk of infection, cytopenia, and impaired wound healing during major surgery, whereas abrupt discontinuation can precipitate ruxolitinib discontinuation syndrome (RDS), an inflammatory rebound syndrome that may be life-threatening. Currently, there are no established perioperative guidelines for the management of ruxolitinib.

Methods

We report a case of a 65-year-old patient with PMF undergoing elective coronary artery bypass graft (CABG) surgery.

Results

Following multidisciplinary discussion with the haematology, ruxolitinib was withheld for 48 hours perioperatively and prophylactic corticosteroids were administered. The patient underwent an uncomplicated surgery and recovery without evidence of infection, thrombocytopaenia, or RDS.

Conclusion

This case highlights the challenges associated with perioperative ruxolitinib management and emphasises the importance of multidisciplinary decision-making and individualized risk assessment. Reporting such cases contributes to the limited literature on guiding perioperative management of JAK inhibitor therapy in patients undergoing major surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesPrimary MyelofibrosisCoronary Artery BypassPerioperative CareJanus Kinase InhibitorsCoronary Artery DiseaseHumansNitrilesPyrimidinesAgedMaleTreatment Outcome

Stichwörter der Autor:innen

cardiac surgerycoronary artery bypass graft surgerymyelofibrosisperioperative managementruxolitinib

Substanzen

PyrazolesruxolitinibNitrilesPyrimidinesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom.
  • Department of Haematology, East Surrey Hospital, Redhill, RH1 5RH, United Kingdom.
  • Department of Perioperative Medicine, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom.

ORCID-Profile: Michael Kay

Zitieren

APA

Kay, M., Yates, M., O'Donovan, E., & Tully, L. (2026). Perioperative Management of Ruxolitinib in Primary Myelofibrosis During Coronary Artery Bypass Graft Surgery. Interdisciplinary CardioVascular and Thoracic Surgery, 41(8). https://doi.org/10.1093/icvts/ivag211

Vancouver

Kay M, Yates M, O'Donovan E, Tully L. Perioperative Management of Ruxolitinib in Primary Myelofibrosis During Coronary Artery Bypass Graft Surgery. Interdisciplinary CardioVascular and Thoracic Surgery. 2026;41(8). doi:10.1093/icvts/ivag211

BibTeX
@article{Kay2026,
  author = {Kay, Michael and Yates, Martin and O'Donovan, Emma and Tully, Lauren},
  title = {Perioperative Management of Ruxolitinib in Primary Myelofibrosis During Coronary Artery Bypass Graft Surgery},
  journal = {Interdisciplinary CardioVascular and Thoracic Surgery},
  year = {2026},
  volume = {41},
  number = {8},
  doi = {10.1093/icvts/ivag211}
}
Kostenlos starten →